Press Release Archive

August 22, 2011 - Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban At European Society of Cardiology Congress 2011

(BUSINESS WIRE)--PRINCETON, N.J.

August 17, 2011 - Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies

(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed

August 14, 2011 - Pfizer Wins Viagra Patent Trial

(BUSINESS WIRE)--Pfizer Inc. announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. in the United States District Court for the Eastern District of Virginia. "We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction," said Amy Schulman, executive vice president and general counsel for Pfizer. "

August 8, 2011 - Pfizer Expands California Centers For Therapeutic Innovation Five Year Partnership With UC San Diego Health Sciences To Accelerate Drug Discovery and Development

(BUSINESS WIRE)--Pfizer Inc. today announced that it will partner with University of California, San Diego Health Sciences through the company’s Centers for Therapeutic Innovation (CTI), a network of collaborative partnerships with top-tier life science research institutions in California, Massachusetts and New York that aims to accelerate and transform drug discovery and development. Pfizer anticipates a potential investment of up

August 3, 2011 - Dana Delany Partners with Caltrate® to Celebrate Women and How They Move the World Every Day through Their Amazing Strength and Contributions

(BUSINESS WIRE)--For more than 25 years, Caltrate® has helped replenish the calcium and vitamin D women need each day in order to keep their bodies active—so they can move the world physically, emotionally and for the causes in which they believe. This year, Caltrate® is partnering with Dana Delany to celebrate women who move our world by issuing a national call-to-action inviting women everywhere to share their individual

August 3, 2011 - NCCN Receives $2M Educational Grant from Pfizer to Support Tailored Quality Improvement Plans at Leading Cancer Centers

(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) announces the development of the first continuing medical education (CME) program to leverage data in the NCCN Oncology Outcomes Database (NCCN Database) to objectively measure the impact of comprehensive performance improvement on patient outcomes. The NCCN Opportunities for Improvement initiative is supported by a three- year, $2 million educational grant

August 1, 2011 - Pfizer Reports Second-Quarter 2011 Results

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Second-Quarter Year-to-Date 2011 2010 Change

August 1, 2011 - Pfizer Completes Sale Of Capsugel Business To KKR

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”), following the receipt of required regulatory clearances, including in the U.S. and the European Union. Under the terms of the previously announced agreement, KKR acquired the Capsugel business for $2.375 billion in cash. Pfizer

July 29, 2011 - Pfizer Provides U.S. Regulatory Update on Prevnar 13® for Use in Adults 50 Years and Older

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company’s supplemental Biologics License Application (sBLA) for use of Prevnar 13®, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 and older. This extends the review period to January 2012. The extension is due to additional data that Pfizer

July 19, 2011 - Pfizer To Acquire Icagen

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen’s fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The aggregate transaction value, including the value of the shares currently owned by Pfizer, is

July 6, 2011 - Pfizer To Explore Strategic Alternatives For Its Animal Health And Nutrition Businesses

(BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) today announced that it is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value. The company is considering options that may include, among others, a full or partial separation of each of these businesses from Pfizer through a spin-off, sale or other

July 5, 2011 - Positive Top-Line Results For Pfizer’s Lyrica In Phase 3 Study Of Patients With Fibromyalgia In Japan

(BUSINESS WIRE)--TOKYO

July 4, 2011 - Pfizer Affirms CHANTIX/CHAMPIX as Important Treatment Option for Smokers Wanting to Quit

(BUSINESS WIRE)--Pfizer said today that the reliable science on varenicline (CHANTIX/CHAMPIX), involving more than 14 clinical trials with more than 7,000 smokers, and the medicine’s approval by regulatory authorities around the world, demonstrate the importance of the medicine as an effective and appropriate treatment option for adult smokers wanting to quit. Pfizer stands behind the benefit/risk profile of Chantix. The company

June 28, 2011 - Pfizer and ChemRar High Tech Center Announce Plans to Explore Innovative Medical Research and Development Partnership in Russia

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) announced today that they have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries. The announcement was made during the BIO International Convention. The two companies will

June 28, 2011 - Pfizer Nutrition Data Demonstrate that Appropriate Early Child Nutrition May Be Linked to Long-Term Health Outcomes in At-Risk Populations and Picky Eaters

(BUSINESS WIRE)--Results from studies presented by Pfizer Nutrition at the 5th Europaediatrics Congress in Vienna provide further evidence that appropriate feeding practices are critical to support the healthy growth and development of at-risk infants and picky eaters facing nutritional challenges. Data from two studies presented at the Congress demonstrate that many infants and children face nutritional challenges, including those who

June 28, 2011 - Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 2, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web

June 27, 2011 - Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer’s filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC). This submission was based on Phase 3 data from the AXIS 1032 trial, comparing axitinib with sorafenib in patients with previously treated advanced RCC, which Pfizer recently presented at the 47th Annual Meeting of the American Society of

June 27, 2011 - Pfizer Announces Data Presentations For Investigational Compounds In Its Lung Cancer Portfolio

(BUSINESS WIRE)--Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 (PF-299) an investigational, oral, pan-HER inhibitor;1 and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,2 at the International Association for the Study of Lung Cancer’s (IASLC) 14th World Conference on Lung Cancer (WCLC), July 3-7 in Amsterdam, The

June 23, 2011 - FDA Complete Response Letter Received for REMOXY

(BUSINESS WIRE)--NEW YORK

June 23, 2011 - Pfizer Declares A 20-Cent Third-Quarter 2011 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent third-quarter 2011 dividend on the company’s common stock, payable September 6, 2011, to shareholders of record at the close of business on August 5, 2011. The third-quarter 2011 cash dividend will be the 291st consecutive quarterly dividend paid by Pfizer.

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.